Médecine

Paramédical

Autres domaines


S'abonner

The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo - 18/04/17

Doi : 10.1016/j.jaad.2016.12.041 
Tasneem F. Mohammad, MD a, Mohammed Al-Jamal, MD b, Iltefat H. Hamzavi, MD a, , John E. Harris, MD, PhD c, Giovanni Leone, MD d, Raúl Cabrera, MD e, Henry W. Lim, MD a, Amit G. Pandya, MD f, Samia M. Esmat, MD g
a Department of Dermatology, Henry Ford Hospital, Detroit, Michigan 
b Department of Dermatology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia 
c Department of Dermatology, The University of Massachusetts Medical School, Worcester, Massachusetts 
d Department of Dermatology, The San Gallicano Institute, Rome, Italy 
e Department of Dermatology, The Clinica Alemana de Santiago de Chile, Santiago, Chile 
f Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas 
g Department of Dermatology, Cairo University, Kasr Al Aini Hospital, Cairo, Egypt 

Reprint requests: Iltefat H. Hamzavi, MD, Henry Ford Hospital, Department of Dermatology, 3031 W Grand Blvd, Ste 800, Detroit, MI 48202.Henry Ford HospitalDepartment of Dermatology3031 W Grand BlvdSte 800DetroitMI48202

Abstract

Background

Treatment of vitiligo with narrowband ultraviolet B light (NBUVB) is an important component of the current standard of care. However, there are no consistent guidelines regarding the dosing and administration of NBUVB in vitiligo, reflected by varied treatment practices around the world.

Objective

To create phototherapy recommendations to facilitate clinical management and identify areas requiring future research.

Methods

The Vitiligo Working Group (VWG) Phototherapy Committee addressed 19 questions regarding the administration of phototherapy over 3 conference calls. Members of the Photomedicine Society and a group of phototherapy experts were surveyed regarding their phototherapy practices.

Results

Based on comparison and analysis of survey results, expert opinion, and discussion held during conference calls, expert recommendations for the administration of NBUVB phototherapy in vitiligo were created.

Limitations

There were several areas that required further research before final recommendations could be made. In addition, no standardized methodology was used during literature review and to assess the strength of evidence during the development of these recommendations.

Conclusion

This set of expert recommendations by the VWG is based on the prescribing practices of phototherapy experts from around the world to create a unified, broadly applicable set of recommendations on the use of NBUVB in vitiligo.

Le texte complet de cet article est disponible en PDF.

Key words : expert recommendation, narrowband phototherapy, pigmentation, UVB, vitiligo


Plan


 Funding sources: None.
 Dr Mohammad is a subinvestigator for Allergan, Ferndale Laboratories, and Estee Lauder. Dr Hamzavi is an investigator for Clinuvel, Estee Lauder, Allergan, Ferndale Laboratories, and Johnson and Johnson, and has received equipment from Johnson and Johnson. Dr Lim is a consultant for L'Oreal, Pierre Fabre, and Mitsubishi Tanabe, and an investigator for Estee Lauder, Ferndale, and Allergan. Drs Leone, Pandya, Al Jamal, Harris, Cabrera, and Esmat have no conflicts of interest to declare.
 Presented at PigmentaryCon 2016, April 2, 2016, Delhi, India.
 Drs Mohammad and Al-Jamal contributed equally to this article.


© 2017  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 76 - N° 5

P. 879-888 - mai 2017 Retour au numéro
Article précédent Article précédent
  • Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea
  • Jung Min Bae, June Hyunkyung Lee, Jae Seung Yun, Byeol Han, Tae Young Han
| Article suivant Article suivant
  • Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases
  • Nina van Beek, Cornelia Dähnrich, Nora Johannsen, Susanne Lemcke, Stephanie Goletz, Franziska Hübner, Giovanni Di Zenzo, Marian Dmochowski, Kossara Drenovska, Shamir Geller, Michael Horn, Cezary Kowalewski, Ljiljana Medenica, Dedee F. Murrell, Aikaterini Patsatsi, Soner Uzun, Snejina Vassileva, Detlef Zillikens, Wolfgang Schlumberger, Enno Schmidt

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.